Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.tcm.2016.08.008 http://scihub22266oqcxt.onion/10.1016/j.tcm.2016.08.008 C5326691!5326691 !27686272     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27686272 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Trends+Cardiovasc+Med 2017 ; 27 (5 ): 352-359 Nephropedia Template TP {{tp|p=27686272 |t=2017. Leveraging human genetics to guide drug target discovery |pdf=|usr=}}{{27686272 }} gab.com Text Leveraging human genetics to guide drug target discovery JO: Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=27686272 #FOAvip Identifying appropriate molecular targets is a critical step in drug development. Despite many advantages, the traditional tools of observational epidemiology and cellular or animal models of disease can be misleading in identifying causal pathways likely to lead to successful therapeutics. Here, we review some favorable aspects of human genetics studies that have the potential to accelerate drug target discovery. These include using genetic studies to identify pathways relevant to human disease, leveraging human genetics to discern causal relationships between biomarkers and disease, and studying genetic variation in humans to predict the potential efficacy and safety of inhibitory compounds aimed at molecular targets. We present some examples taken from studies of plasma lipids and coronary artery disease to highlight how human genetics can accelerate therapeutics development. Twit Text FOAVip Leveraging human genetics to guide drug target discovery ????Trends Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=27686272 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27686272 #FOAvip English Wikipedia <ref>{{Cite pmid|27686272 }}</ref> Leveraging human genetics to guide drug target discovery #MMPMID27686272 Stitziel NO ; Kathiresan S Trends Cardiovasc Med 2017[Jul]; 27 (5 ): 352-359 PMID27686272 show ga Identifying appropriate molecular targets is a critical step in drug development. Despite many advantages, the traditional tools of observational epidemiology and cellular or animal models of disease can be misleading in identifying causal pathways likely to lead to successful therapeutics. Here, we review some favorable aspects of human genetics studies that have the potential to accelerate drug target discovery. These include using genetic studies to identify pathways relevant to human disease, leveraging human genetics to discern causal relationships between biomarkers and disease, and studying genetic variation in humans to predict the potential efficacy and safety of inhibitory compounds aimed at molecular targets. We present some examples taken from studies of plasma lipids and coronary artery disease to highlight how human genetics can accelerate therapeutics development. |*Genomics [MESH] |Animals [MESH] |Cardiovascular Agents/adverse effects/*therapeutic use [MESH] |Cardiovascular Diseases/*drug therapy/*genetics/metabolism/physiopathology [MESH] |Drug Discovery/*methods [MESH] |Genetic Predisposition to Disease [MESH] |Humans [MESH] |Molecular Targeted Therapy [MESH] |Pharmacogenetics [MESH] |Phenotype [MESH] |Risk Factors [MESH]Leveraging human genetics to guide drug target discovery (epmc).pdf DeepDyve Pubget Overpricing